Dr Jake P. Mann BMedSc MBChB(Hons) PhD MRCP MRCPCH

Dr Jake P. Mann

Department of Immunology and Immunotherapy
Birmingham Health Partners Clinician Scientist
Honorary Consultant Paediatric Hepatologist

Contact details

Address
Centre for Liver and Gastrointestinal Research
Institute of Biomedical Research
College of Medicine and Health
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Dr. Jake P. Mann is a clinician scientist and consultant paediatric hepatologist. He uses cutting-edge techniques to make discoveries into the drivers of children’s liver fibro-inflammation. He is a key opinion leader in paediatric steatotic liver disease.

Qualifications

  • Member of GMC Specialist Register in Paediatric gastroenterology, hepatology, and nutrition, General Medical Council (GMC), 2024
  • PhD in Clinical Biochemistry, University of Cambridge, 2022
  • Member of Royal College of Paediatricians and Child Health, 2016
  • Member of Royal College of Physicians, 2014
  • MBChB (Bachelor of Medicine and Surgery), University of Birmingham, 2012
  • BMedSc (Medical Science), University of Birmingham, 2009

Biography

Dr Jake Mann is a clinician–scientist specialising in paediatric hepatology, with a focus on the mechanisms of fibrosis and inflammation in childhood liver disease. His research programme studies rare, severe conditions (particularly biliary atresia) to identify conserved pathways that may represent therapeutic targets in more common diseases such as metabolic dysfunction–associated steatotic liver disease (MASLD).

His laboratory uses advanced molecular approaches, including single-cell and spatial transcriptomics in human liver tissue, to interrogate processes of liver injury and repair. He has a particular interest in the ductular reaction and its role across cholestatic and metabolic liver diseases.

Clinically, Dr Mann has led the development of a specialist paediatric MASLD service, establishing a coordinated, networked model of care that supports clinicians across the UK.

Alongside his mechanistic work, Dr Mann contributes to shaping clinical practice and policy in paediatric MASLD. He led the 2026 European paediatric MASLD guideline development and has a strong interest in how evidence is translated into real-world care. His clinical research includes studies of long-term outcomes in children with MASLD and the use of non-invasive imaging tools for risk stratification.

Dr Mann is committed to supporting the development of clinical academic trainees, particularly in paediatrics. He runs a regular webinar programme, writes an active blog (https://jakepmann.com/), and mentors several trainees.

He is keen to support motivated paediatric clinical trainees interested in pursuing research careers, particularly those preparing applications for funded PhD fellowships. Opportunities are available across paediatric MASLD and fibro-inflammatory liver disease, spanning clinical, translational, and data-driven research. Please get in touch to discuss potential projects and mentorship.

Teaching

  • BSc Biomedical Science Research Project Supervisor
  • MSc Immunology Research Project Supervisor

Postgraduate supervision

Projects are available in paediatric MASLD and fibro-inflammatory paediatric liver disease.
Please get in touch to discuss potential projects and mentorship.

Research

1. KidsMASLD-Map: decoding paediatric steatotic liver disease to identify new treatments

This project aims to characterise the liver transcriptome across the spectrum of paediatric MASLD and map expression to clinical outcomes (e.g. diabetes, cirrhosis). This project will broaden and deepen our mechanistic understanding of paediatric MASLD and facilitate computational drug screening via transcriptomics to allow drug repurposing trials.

2. Mechanisms of fibro-inflammation in rapidly progressive biliary atresia

We have generated a single-cell RNA sequencing and spatial transcriptomic dataset from children with biliary atresia and controls. Pathways enriched in rapidly progressive disease are followed-up with mechanistic ex vivo studies using primary human liver cells.